Otsuka Pharmaceutical Co., Ltd.
"Epi Diary" - An Epilepsy Diary Application for iOS
A New Communication Tool for Patients with Epilepsy and their Physicians Now Available at
- "Epi Diary" enables patients with epilepsy and their caregivers to keep daily records of health conditions, symptoms, and drug compliance, using an iPhone. Patients with epilepsy can use this iOS diary application as a communication tool to share with physicians and to discuss their optimal treatment.
- Patients with epilepsy often require long years of treatment, and therefore it is desirable that they experience fewer if any seizures whilst minimizing treatment side effects. However, patients often have difficulties in fully communicating their recent condition when visiting physicians.
- 0.6 million to 1 million people are said to be living with epilepsy in Japan, at a prevalence rate of 5 to 10 people in every 1,000 (0.5～1%), suggesting the need for assisting tools like "Epi Diary". Epilepsy occurs most frequently in children under the age of 3, but elderly people are also prone to newly-onset epilepsy from cerebrovascular disorders.
Otsuka Pharmaceutical Co., Ltd. (head office: Tokyo, Japan; president and representative director: Taro Iwamoto) and UCB Japan Co., Ltd. (head office: Tokyo, Japan; president and representative director: Joel Peterson) announced the development and launch of iOS application "Epi Diary" as of April 1.
"Epi Diary" was developed together with QLife, Inc. (head office: Tokyo, Japan), a medical media company, who will also support us operate the application.